Loading clinical trials...
Loading clinical trials...
Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)
Conditions
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group)
Cyclophosphamide plus rituximab placebo (control group)
+3 more
Locations
8
United States
University of Alabama
Birmingham, Alabama, United States
Johns Hopkins University
Baltimore, Maryland, United States
Boston University
Boston, Massachusetts, United States
Mayo Clinic Foundation
Rochester, Minnesota, United States
Hospital for Special Surgery
New York, New York, United States
Duke University
Durham, North Carolina, United States
Start Date
January 1, 2005
Primary Completion Date
December 1, 2008
Completion Date
January 1, 2010
Last Updated
April 21, 2017
NCT07413341
NCT05734404
NCT03004326
NCT06887062
NCT07339540
NCT07089121
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions